Sep 03, 2026
Walmart Stock Gains on Broad Market Rally and New Delivery Partnership

Shares of Walmart Inc. (NASDAQ:WMT) are trading higher Thursday afternoon as the retail giant benefits from broader market tailwinds and fresh expansion within its delivery ecosystem. Here’s what investors need to know. Walmart stock is showing upward movement. Why is…

Sep 03, 2026
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 mutations. The clinical-stage biotechnology firm develops multispecific immuno-oncology therapeutics to…

Sep 03, 2026
Why Is HUTCHMED Stock Soaring Thursday?

HUTCHMED (China) Limited (NASDAQ:HCM) stock is surging after announcing an exclusive licensing agreement with GSK plc (NYSE:GSK) for the cancer drug candidate HMPL-A830. Through this partnership, the GSK subsidiary obtains exclusive rights to develop and commercialize the therapy globally, excluding…

Sep 03, 2026
AbbVie Touts Positive Data For Multiple Myeloma Drug

AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The study demonstrated that the drug outperformed standard therapies, meeting its primary goals for objective…

Sep 03, 2026
Why Is Webull Stock Surging on Thursday?

Webull Corp. (NASDAQ:BULL) stock is surging Thursday primarily due to a broader sector-wide rally in online retail brokerages. The Nasdaq is up 1.16% while the S&P 500 has gained 1.01%. Sustained momentum from crypto-linked stocks is supporting the retail brokerage…

Sep 03, 2026
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease. The clinical-stage biotechnology firm is developing therapeutics for patients suffering from…

Sep 03, 2026
Campbell’s Turns Back to Price Hikes As Inflation Squeezes Margins

The Campbell’s Company (NASDAQ:CPB) stock fell Thursday after the company reported mixed fourth-quarter results and issued fiscal 2027 adjusted EPS guidance below estimates.Campbell’s Earnings SnapshotAdjusted EPS of 39 cents was in line with estimates. Sales of $2.137 billion missed the…